These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 30922541)
1. Role of Ranolazine in Reducing Angina, Subsequent Revascularization, and Healthcare Expenditures in Stable Ischemic Heart Disease. Rasalingam R; Boden WE Am J Cardiol; 2019 May; 123(10):1729-1731. PubMed ID: 30922541 [No Abstract] [Full Text] [Related]
2. Revascularization Rates and Associated Costs in Patients With Stable Ischemic Heart Disease Initiating Ranolazine Versus Traditional Antianginals as Add-on Therapy. Meyer N; Tran O; Hartsfield C; Nguyen L; Kazi DS; Koch B Am J Cardiol; 2019 May; 123(10):1602-1609. PubMed ID: 30832963 [TBL] [Abstract][Full Text] [Related]
3. Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial. Weisz G; Généreux P; Iñiguez A; Zurakowski A; Shechter M; Alexander KP; Dressler O; Osmukhina A; James S; Ohman EM; Ben-Yehuda O; Farzaneh-Far R; Stone GW; Lancet; 2016 Jan; 387(10014):136-45. PubMed ID: 26474810 [TBL] [Abstract][Full Text] [Related]
4. Relationship Between Optimism and Outcomes in Patients With Chronic Angina Pectoris. Fanaroff AC; Prather K; Brucker A; Wojdyla D; Davidson-Ray L; Mark DB; Williams RB; Barefoot J; Weisz G; Ben-Yehuda O; Stone GW; Ohman EM; Alexander KP Am J Cardiol; 2019 May; 123(9):1399-1405. PubMed ID: 30771861 [TBL] [Abstract][Full Text] [Related]
5. Effects of Ranolazine in Patients With Chronic Angina in Patients With and Without Percutaneous Coronary Intervention for Acute Coronary Syndrome: Observations From the MERLIN-TIMI 36 Trial. Gutierrez JA; Karwatowska-Prokopczuk E; Murphy SA; Belardinelli L; Farzaneh-Far R; Walker G; Morrow DA; Scirica BM Clin Cardiol; 2015 Aug; 38(8):469-75. PubMed ID: 26059896 [TBL] [Abstract][Full Text] [Related]
6. Ranolazine: effects on ischemic heart. Rognoni A; Barbieri L; Cavallino C; Bacchini S; Veia A; Degiovanni A; Rametta F; Nardi F; Lazzero M; Lupi A; Bongo AS Recent Pat Cardiovasc Drug Discov; 2013 Dec; 8(3):197-203. PubMed ID: 23961914 [TBL] [Abstract][Full Text] [Related]
7. Management of myocardial ischemia. Is ranolazine needed? For all or some patients with myocardial ischemia? Cocco G Expert Opin Pharmacother; 2012 Dec; 13(17):2429-32. PubMed ID: 23121536 [TBL] [Abstract][Full Text] [Related]
8. Should ranolazine be used for all patients with ischemic heart disease or only for symptomatic patients with stable angina or for those with refractory angina pectoris? A critical appraisal. Thadani U Expert Opin Pharmacother; 2012 Dec; 13(17):2555-63. PubMed ID: 23121448 [TBL] [Abstract][Full Text] [Related]
9. Coronary artery disease: a dam in the river for ranolazine. Head SJ; Kappetein AP Lancet; 2016 Jan; 387(10014):100-2. PubMed ID: 26474812 [No Abstract] [Full Text] [Related]
10. Impact of ranolazine on clinical outcomes and healthcare resource utilization in patients with refractory angina pectoris. Ling H; Packard KA; Burns TL; Hilleman DE Am J Cardiovasc Drugs; 2013 Dec; 13(6):407-12. PubMed ID: 23873327 [TBL] [Abstract][Full Text] [Related]
12. Effects of Ranolazine on Angina and Quality of Life After Percutaneous Coronary Intervention With Incomplete Revascularization: Results From the Ranolazine for Incomplete Vessel Revascularization (RIVER-PCI) Trial. Alexander KP; Weisz G; Prather K; James S; Mark DB; Anstrom KJ; Davidson-Ray L; Witkowski A; Mulkay AJ; Osmukhina A; Farzaneh-Far R; Ben-Yehuda O; Stone GW; Ohman EM Circulation; 2016 Jan; 133(1):39-47. PubMed ID: 26555329 [TBL] [Abstract][Full Text] [Related]
14. Long-Term Preservation of Left Ventricular Systolic Function in Patients With Refractory Angina Pectoris and Inducible Myocardial Ischemia on Optimal Medical Therapy. Slavich M; Maranta F; Fumero A; Godino C; Giannini F; Oppizzi M; Colombo A; Fragasso G; Margonato A Am J Cardiol; 2016 May; 117(10):1558-1561. PubMed ID: 27055755 [TBL] [Abstract][Full Text] [Related]
15. New Anti-Anginal Drugs: Ranolazine. Cavallino C; Facchini M; Veia A; Bacchni S; Rosso R; Rognoni A; Rametta F; Lupi A; Bongo AS Cardiovasc Hematol Agents Med Chem; 2015; 13(1):14-20. PubMed ID: 25544118 [TBL] [Abstract][Full Text] [Related]
16. Effect of Ranolazine on Ischemic Myocardium IN Patients With Acute Cardiac Ischemia (RIMINI-Trial): A Randomized Controlled Pilot Trial. Schwemer TF; Radziwolek L; Deutscher N; Diermann N; Sehner S; Blankenberg S; Friedrich FW J Cardiovasc Pharmacol Ther; 2019 Jan; 24(1):62-69. PubMed ID: 29938533 [TBL] [Abstract][Full Text] [Related]
17. Influence of trimetazidine and ranolazine on endothelial function in patients with ischemic heart disease. Rehberger-Likozar A; Šebeštjen M Coron Artery Dis; 2015 Dec; 26(8):651-6. PubMed ID: 26049922 [TBL] [Abstract][Full Text] [Related]
18. Role of Ranolazine in cardiovascular disease and diabetes: Exploring beyond angina. Banerjee K; Ghosh RK; Kamatam S; Banerjee A; Gupta A Int J Cardiol; 2017 Jan; 227():556-564. PubMed ID: 27838121 [TBL] [Abstract][Full Text] [Related]
19. Revascularization trumps medicine for patients with type 2 diabetes mellitus and chronic angina (or does it?). Marso SP Circulation; 2011 Apr; 123(14):1489-91. PubMed ID: 21444884 [No Abstract] [Full Text] [Related]
20. The use of ranolazine in non-anginal cardiovascular disorders: A review of current data and ongoing randomized clinical trials. Mihos CG; Krishna RK; Kherada N; Larrauri-Reyes M; Tolentino A; Santana O Pharmacol Res; 2016 Jan; 103():49-55. PubMed ID: 26546970 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]